NASDAQ:TTOO T2 Biosystems (TTOO) Stock Price, News & Analysis → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Free TTOO Stock Alerts $2.90 +0.16 (+5.84%) (As of 03:10 PM ET) Add Compare Share Share Today's Range$2.70▼$2.9050-Day Range$2.72▼$5.5552-Week Range$2.60▼$70.00Volume102,148 shsAverage Volume271,401 shsMarket Capitalization$15.98 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get T2 Biosystems alerts: Email Address Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. About T2 Biosystems Stock (NASDAQ:TTOO)T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood test that identifies blood stream infections that causes sepsis and candidemia; T2Bacteria panel, a direct-from-blood test, which detects bacterial pathogens associated with sepsis; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus. In addition, it is developing T2Biothreat panel for detection of biothreat pathogens; comprehensive sepsis panel to detect bloodstream infections caused by bacterial and Candida species, and antibiotic resistant markers; T2Cauris panel to provide direct detection of the emerging superbug Candida auris in patient skin, patient blood, and hospital environmental samples; and T2Lyme panel, a direct-from-blood test panel designed to run on the T2Dx Instrument to identify the bacteria that cause Lyme disease. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.Read More TTOO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TTOO Stock News HeadlinesApril 24, 2024 | globenewswire.comT2 Biosystems to Report First Quarter 2024 Financial Results and Business Updates on May 6, 2024April 22, 2024 | americanbankingnews.comT2 Biosystems (NASDAQ:TTOO) versus Anika Therapeutics (NASDAQ:ANIK) Head to Head ContrastApril 26, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.April 13, 2024 | investing.comT2 Biosystems converts $15M loan to equity, aims for Nasdaq complianceApril 12, 2024 | finanznachrichten.deT2 Biosystems, Inc.: T2 Biosystems Shareholders Vote for CRG Debt Conversion into EquityApril 11, 2024 | globenewswire.comT2 Biosystems Shareholders Vote for CRG Debt Conversion into EquityMarch 28, 2024 | finanznachrichten.deT2 Biosystems, Inc.: T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.March 28, 2024 | globenewswire.comT2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.April 26, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.March 20, 2024 | finanznachrichten.deT2 Biosystems, Inc.: T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business UpdatesMarch 20, 2024 | markets.businessinsider.comT2 Biosystems Targets Commercial Launch Of T2Lyme Panel In Q3 - Quick FactsMarch 20, 2024 | globenewswire.comT2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business UpdatesMarch 19, 2024 | globenewswire.comT2 Biosystems to Host Investor Call on March 20, 2024 to Unveil its T2Lyme Launch Plans and Provide Additional Business UpdatesMarch 18, 2024 | globenewswire.comT2 Biosystems Announces New Publication Highlighting the Clinical Benefits and Performance of the T2Resistance PanelMarch 12, 2024 | investorplace.comTTOO Stock: T2 Biosystems Has Until May 20 to Regain Nasdaq ComplianceMarch 12, 2024 | finanznachrichten.deT2 Biosystems, Inc.: T2 Biosystems Receives Extension to Comply with Nasdaq Listing RequirementMarch 12, 2024 | globenewswire.comT2 Biosystems Receives Extension to Comply with Nasdaq Listing RequirementFebruary 16, 2024 | money.usnews.comT2 Biosystems IncFebruary 16, 2024 | finance.yahoo.comT2 Biosystems, Inc. (NASDAQ:TTOO) Q4 2023 Earnings Call TranscriptFebruary 16, 2024 | finanznachrichten.deT2 Biosystems, Inc.: T2 Biosystems Announces Commercial Expansion Through Distributors in Europe and AsiaFebruary 16, 2024 | finance.yahoo.comQ4 2023 T2 Biosystems Inc Earnings CallFebruary 15, 2024 | finance.yahoo.comT2 Biosystems Announces Commercial Expansion Through Distributors in Europe and AsiaFebruary 15, 2024 | finance.yahoo.comT2 Biosystems Announces Agreement with CRG for the Conversion of $15 Million of CRG Term Loan into EquityFebruary 15, 2024 | finance.yahoo.comT2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2023 Financial ResultsFebruary 15, 2024 | globenewswire.comT2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2023 Financial ResultsFebruary 15, 2024 | globenewswire.comT2 Biosystems Announces Agreement with CRG for the Conversion of $15 Million of CRG Term Loan into EquityFebruary 15, 2024 | globenewswire.comT2 Biosystems Announces Commercial Expansion Through Distributors in Europe and AsiaSee More Headlines Receive TTOO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for T2 Biosystems and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today4/26/2024Next Earnings (Confirmed)5/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:TTOO CUSIPN/A CIK1492674 Webwww.t2biosystems.com Phone(781) 761-4646Fax781-357-3080Employees113Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-50,080,000.00 Net Margins-696.19% Pretax Margin-696.19% Return on EquityN/A Return on Assets-129.79% Debt Debt-to-Equity RatioN/A Current Ratio0.45 Quick Ratio0.36 Sales & Book Value Annual Sales$7.19 million Price / Sales2.18 Cash FlowN/A Price / Cash FlowN/A Book Value($6.91) per share Price / Book-0.41Miscellaneous Outstanding Shares5,510,000Free Float5,506,000Market Cap$15.70 million OptionableOptionable Beta0.11 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. John J. Sperzel III (Age 61)B.Sc., President, CEO & Chairman Comp: $865.5kMr. John M. Sprague CPA (Age 66)Chief Financial Officer Comp: $581kMr. Michael Terrence Gibbs Esq. (Age 53)Senior VP, General Counsel & Company Secretary Comp: $622.6kMs. Kelley J. Morgan (Age 48)Chief People Officer Mr. Brett A. Giffin (Age 65)Chief Commercial Officer Dr. Roger Smith Ph.D. (Age 59)Senior Vice President of Science Research & Development More ExecutivesKey CompetitorsPetVivoNASDAQ:PETVNEXGELNASDAQ:NXGLBiotricityNASDAQ:BTCYPAVmedNASDAQ:PAVMMicrobot MedicalNASDAQ:MBOTView All CompetitorsInsidersGroup L.P. CrSold 59,812 sharesTotal: $1.14 M ($19.00/share)Group L.P. CrSold 2,500 sharesTotal: $62,500.00 ($25.00/share)Group L.P. CrSold 63,382 sharesTotal: $1.90 M ($30.00/share)Group L.P. CrSold 104,014 sharesTotal: $3.85 M ($37.00/share)View All Insider Transactions TTOO Stock Analysis - Frequently Asked Questions How have TTOO shares performed in 2024? T2 Biosystems' stock was trading at $6.28 at the beginning of 2024. Since then, TTOO shares have decreased by 54.3% and is now trading at $2.87. View the best growth stocks for 2024 here. Are investors shorting T2 Biosystems? T2 Biosystems saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 396,900 shares, an increase of 34.4% from the March 15th total of 295,400 shares. Based on an average daily trading volume, of 255,400 shares, the short-interest ratio is presently 1.6 days. Currently, 11.6% of the company's stock are sold short. View T2 Biosystems' Short Interest. When is T2 Biosystems' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024. View our TTOO earnings forecast. How can I listen to T2 Biosystems' earnings call? T2 Biosystems will be holding an earnings conference call on Monday, May 6th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link. How were T2 Biosystems' earnings last quarter? T2 Biosystems, Inc. (NASDAQ:TTOO) issued its quarterly earnings results on Thursday, November, 4th. The medical equipment provider reported ($400.00) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($400.00). The medical equipment provider earned $7.43 million during the quarter. During the same quarter last year, the business earned ($400.00) earnings per share. When did T2 Biosystems' stock split? T2 Biosystems shares reverse split before market open on Friday, October 13th 2023. The 1-100 reverse split was announced on Friday, October 13th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, October 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. What guidance has T2 Biosystems issued on next quarter's earnings? T2 Biosystems updated its fourth quarter 2023 earnings guidance on Friday, February, 16th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.7 million-$1.7 million, compared to the consensus revenue estimate of $2.4 million. What is John McDonough's approval rating as T2 Biosystems' CEO? 36 employees have rated T2 Biosystems Chief Executive Officer John McDonough on Glassdoor.com. John McDonough has an approval rating of 54% among the company's employees. This puts John McDonough in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of T2 Biosystems own? Based on aggregate information from My MarketBeat watchlists, some companies that other T2 Biosystems investors own include Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Tonix Pharmaceuticals (TNXP), OPKO Health (OPK), SCYNEXIS (SCYX), Biocept (BIOC), Heat Biologics (HTBX), NVIDIA (NVDA) and Vaxart (VXRT). How do I buy shares of T2 Biosystems? Shares of TTOO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TTOO) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”AltimetryJim Cramer’s “The Biggest Drug Ever”Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding T2 Biosystems, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
